News & Events

News

All categories

Earnings

Press Release

All years

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Announces U.S. Registrational Pathway and Updated Clinical Development Plan for AFM13 at R&D Day

December 7, 2018

Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors

December 3, 2018

Affimed to Host Research & Development Day on Friday, December 7, 2018 in New York City

November 28, 2018

Affimed to Present at the Jefferies 2018 London Healthcare Conference

November 8, 2018

Affimed Reports Financial Results for Third Quarter 2018 and Operational Progress

November 7, 2018

Affimed Announces Oral Presentation and Five Poster Presentations at the 2018 American Society of Hematology Annual Meeting

November 1, 2018

Affimed Announces Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018

October 31, 2018

Affimed Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase 1 Program on Clinical Hold

October 8, 2018

Affimed to Present at the 2018 Wells Fargo Securities Healthcare Conference

August 30, 2018

Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets

August 27, 2018

Events

All

Scientific

Investors

23Mar

Innate Killer Summit

March 23 - 25, 2021 (virtual)

Webcasts
More events